CTAPIII/CXCL7: a novel biomarker for early diagnosis of lung cancer

Abstract

It is desirable to have a biomarker which can facilitate low‐dose CT in diagnosis of early stage lung cancer. CTAPIII/CXCL7 is reported to be a potential biomarker for diagnosis of early lung cancer. In this study, we investigated the serum level of CTAPIII/CXCL7 in patients at different stage of lung cancer and the diagnostic efficacy of CTAPIII/CXCL7 in NSCLC. The plasma level of CTAPIII/CXCL7 was assayed by ELISA. CEA, SCCAg, and Cyfra211 were measured using a commercial chemiluminescent microparticle immunoassay. A total of 419 subjects were recruited, including 265 NSCLC patients and 154 healthy individuals. The subjects were randomly assigned to a training set and a test set. Receiver operating characteristic (ROC) and binary logistic regression analyses were conducted to evaluate the diagnostic efficacy and establish diagnostic mathematical model. Plasma CTAPIII/CXCL7 levels were significantly higher in NSCLC patients than in controls, which was independent of the stage of NSCLC. The diagnostic efficiency of CTAPIII/CXCL7 in NSCLC (training set: area under ROC curve (AUC) 0.806, 95% CI: 0.748–0.863; test set: AUC 0.773, 95% CI: 0.711–0.835) was greater than that of SCCAg, Cyfra21‐1, or CEA. The model combining CTAPIII/CXCL7 with CEA, SCCAg, and Cyfra21‐1 was more effective for NSCLC diagnosis than CTAPIII/CXCL7 alone. In addition, plasma level of CTAPIII/CXCL7 may contribute to the early diagnosis of NSCLC. CTAPIII/CXCL7 can be used as a plasma biomarker for the diagnosis of NSCLCs, particularly early stage lung cancer, with relatively high sensitivity and specificity.

LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis

“…1,2 Many patients with NSCLC were diagnosed at the advanced stage. 3 At present, the treatment methods are limited for patients with advanced and metastatic NSCLC. Obviously, it is urgent to discover indicators for early diagnosis and new therapeutic targets.…”

Prognostic Predictors Do Not Equate to Predictors of Chemotherapy Benefit in HR-Positive, HER2-Negative Breast Cancer: A Population-Based Study

“…In colorectal cancer, the Iroquois Homeobox 6 (IRX6) expression has been reported to be lower in tumor samples and was a prognostic predictor [30]. Pro-platelet basic protein (PPBP) was also known as C-X-C motif chemokine ligand 7 (CXCL7), the overexpression of which has been reported to promote cell proliferation in vivo and in vitro, and it has been proposed as a novel biomarker for the diagnosis of lung cancer and renal cell carcinoma [31][32][33]. Zhou et al reported that Empty spiracles homeobox 1 (EMX1) was a potential target of miR-497, which was recognized as a tumor suppressor in many cancers, and the high expression of EMX1 was related to advanced clinicopathologic characteristics in endometrial cancer [34].…”

Utility of Circulating Cell-Free RNA Analysis for the Characterization of Global Transcriptome Profiles of Multiple Myeloma Patients

“…Studies have reported the overexpression of most of these genes in multiple cancers, with the exception of CH507-9B2.3 [50,51,52,53,54]; however, they have also been found to be down-regulated in some specific cancers. For example, the chemokine PPBP (pro-platelet basic protein), also known as CXCL7, is decreased in pancreatic and ovarian cancers [55]. The eukaryotic translation elongation factors EEF1B2 and EEF2 are down-regulated in breast, esophageal, and lung cancers while EEF1B2 is found with repression in some other cancer types, such as head and neck, leukemia, and pancreatic cancer [54].…”